Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

  1. Balar, A.V.
  2. Galsky, M.D.
  3. Rosenberg, J.E.
  4. Powles, T.
  5. Petrylak, D.P.
  6. Bellmunt, J.
  7. Loriot, Y.
  8. Necchi, A.
  9. Hoffman-Censits, J.
  10. Perez-Gracia, J.L.
  11. Dawson, N.A.
  12. van der Heijden, M.S.
  13. Dreicer, R.
  14. Srinivas, S.
  15. Retz, M.M.
  16. Joseph, R.W.
  17. Drakaki, A.
  18. Vaishampayan, U.N.
  19. Sridhar, S.S.
  20. Quinn, D.I.
  21. Durán, I.
  22. Shaffer, D.R.
  23. Eigl, B.J.
  24. Grivas, P.D.
  25. Yu, E.Y.
  26. Li, S.
  27. Kadel, E.E.
  28. Boyd, Z.
  29. Bourgon, R.
  30. Hegde, P.S.
  31. Mariathasan, S.
  32. Thåström, A.
  33. Abidoye, O.O.
  34. Fine, G.D.
  35. Bajorin, D.F.
  36. Show all authors +
Journal:
The Lancet

ISSN: 1474-547X 0140-6736

Year of publication: 2017

Volume: 389

Issue: 10064

Pages: 67-76

Type: Article

DOI: 10.1016/S0140-6736(16)32455-2 GOOGLE SCHOLAR

Sustainable development goals